articleScience Translational MedicineJan 21, 2026Closed access

Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction–associated steatohepatitis

CNChittampalli N. YashaswiniBCBruno CogliatiTQTianyue QinTTTran ToTWThomas Williamson

Icahn School of Medicine at Mount Sinai · Universidade de São Paulo · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Hepatic fibrosis is a key predictor of mortality in liver disease, driven by fibrogenic hepatic stellate cells (HSCs). Targeting these fibrogenic cells may therefore offer a therapeutic approach for hepatic fibrosis. We previously showed that in vivo-generated chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein alpha (FAP) reduced murine cardiac fibrosis. Here, we explored the antifibrotic potential of this in vivo-generated anti-FAP CAR T cell therapy in metabolic dysfunction-associated steatohepatitis (MASH), a highly prevalent disease with no approved antifibrotic therapies. We first established that FAP expression in both human and murine MASH is specific to HSCs. We then used…

Citation impact

8
total citations
FWCI
92.83
Percentile
100%
References
80
Too recent for citation history.

Authors

16

Topics & keywords

Topics
Keywords
  • Hepatic stellate cell
  • Steatohepatitis
  • Fibrosis
  • Inflammation
  • Immune system
  • In vivo
  • Cell therapy
  • Hepatic fibrosis
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding